Kinetics of W3/25 anti-rat CD4 monoclonal antibody studies on optimal doses and time-related effects

被引:8
作者
Caballero, F [1 ]
Pelegrí, C [1 ]
Castell, M [1 ]
Franch, A [1 ]
Castellote, C [1 ]
机构
[1] Univ Barcelona, Fac Pharm, Unit Physiol, E-08028 Barcelona, Spain
来源
IMMUNOPHARMACOLOGY | 1998年 / 39卷 / 02期
关键词
anti-rat CD4; W3/25; MoAb kinetics; FACS; CD4; down-regulation;
D O I
10.1016/S0162-3109(98)00011-3
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Although anti-CD4 monoclonal antibodies (MoAb) have been proven successful in preventing or treating adjuvant arthritis, little is known about the duration of the effects of these MoAb and their pharmacokinetics. In this work, we report the effects of a mouse anti-rat CD4 MoAb, named W3/25, on peripheral blood lymphocytes from female Wistar rats. Animals received a single dose of W3/25, from 1 to 3 mg, and blood was sampled at different time points from 0 h to 15 days after MoAb administration. After erythrocyte lysis, samples were stained by indirect immunofluorescence and analyzed by flow cytometry. Pharmacokinetic data were studied by assessing plasma levels of mouse IgG1 by ELISA-sandwich. W3/25 produced the down-regulation of surface CD4 molecule as early as 20 min after its administration at doses of 2 and 3 mg. The same effect was seen 30 min after a dose of 1 mg. The recovery of lymphocytes with normal expression of CD4 also depended of the dose administered. Thus, CD4(+) lymphocytes were recovered at 48, 72 and 96 h in rats treated with 1, 2 or 3 mg of W3/25, respectively. Plasma levels of free antibody were detectable from 20 min to 72 h, 60 min to 48 h and 60 min to 24 h after administration of 3, 2 and 1 mg, respectively, of W3/25. The mouse IgG1 MoAb used in this study followed a two-compartment model and its behavior was linear. (C) 1998 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:83 / 91
页数:9
相关论文
共 25 条
[1]  
[Anonymous], PROTEIN PHARMACOKINE
[2]   MONOCLONAL-ANTIBODIES AND ARTHRITIS [J].
BILLINGHAM, MEJ ;
HICKS, C ;
CARNEY, S .
AGENTS AND ACTIONS, 1990, 29 (1-2) :77-87
[3]   2 SUBSETS OF RAT LYMPHOCYTES-T DEFINED WITH MONOCLONAL-ANTIBODIES [J].
BRIDEAU, RJ ;
CARTER, PB ;
MCMASTER, WR ;
MASON, DW ;
WILLIAMS, AF .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1980, 10 (08) :609-615
[4]   Percentage of anti-CD4 monoclonal antibody-coated lymphocytes in the rheumatoid joint is associated with clinical improvement - Implications for the development of immunotherapeutic dosing regimens [J].
Choy, EHS ;
Pitzalis, C ;
Cauli, A ;
Bijl, JA ;
Schantz, A ;
Woody, J ;
Kingsley, GH ;
Panayi, GS .
ARTHRITIS AND RHEUMATISM, 1996, 39 (01) :52-56
[5]  
Delmonice FL, 1996, CLIN TRANSPLANT, V10, P397
[6]  
EMMRICH F, 1994, IMMUNOPHARMACOLOGY J, P87
[7]   BLOOD-B, BLOOD-T, BLOOD-CD4+ AND BLOOD-CD8+ LYMPHOCYTES IN FEMALE WISTAR RATS [J].
FRANCH, A ;
CASTELLOTE, C ;
PELEGRI, C ;
TOLOSA, E ;
CASTELL, M .
ANNALS OF HEMATOLOGY, 1993, 67 (03) :115-118
[8]   THE PROGRESSION OF THE INFLAMMATION IN ESTABLISHED COLLAGEN-INDUCED ARTHRITIS CAN BE ALTERED BY TREATMENTS WITH IMMUNOLOGICAL OR PHARMACOLOGICAL AGENTS WHICH INHIBIT T-CELL ACTIVITIES [J].
HOM, JT ;
BUTLER, LD ;
RIEDL, PE ;
BENDELE, AM .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1988, 18 (06) :881-888
[9]   A PHASE 1A CLINICAL-TRIAL OF LYM-1 MONOCLONAL-ANTIBODY SEROTHERAPY IN PATIENTS WITH REFRACTORY B-CELL MALIGNANCIES [J].
HU, E ;
EPSTEIN, AL ;
NAEVE, GS ;
GILL, I ;
MARTIN, S ;
SHERROD, A ;
NICHOLS, P ;
CHEN, D ;
MAZUMDER, A ;
LEVINE, AM .
HEMATOLOGICAL ONCOLOGY, 1989, 7 (02) :155-166
[10]  
KINNE RW, 1993, J NUCL MED, V34, P92